A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency

Inclusion Criteria: 1. Prepubertal children with GHD in Tanner Stage 1 2. Baseline HT at least -2.0 SD below the mean HT for CA and sex (HT SDS ≤ 2.0). 3. Body mass index (BMI) within ±2.0 SD of the mean BMI for BA and sex. 4. Growth hormone stimulation tests: ≤10 ng/mL 5. Baseline IGF 1 level of at least 1.0 SD below the mean IGF 1 level standardized for age and sex (IGF 1 SDS ≤-1.0) 6. Normal 46 XX karyotype for girls. 7. Children with multiple hormonal deficiencies must be on stable replacement therapy for other hypothalamo-pituitary axes for at least 3 months 8. Written, signed informed consent of the parent(s) or legal guardian(s) of the participant and written assent of the participant Exclusion Criteria: 1. BA≥CA 2. Prior exposure to rhGH, long-acting growth hormones, or IGF 1 therapy. 3. Major medical conditions or presence of contraindication to human growth hormone (hGH) treatment 4. Participation in any other trial of an investigational agent within 3 months prior to Screening. 5. Any reason per investigator's discretion